Sunitinib-induced severe hypothyroidism with cardiac compromise

Area of Science:

• Oncology
• Endocrinology

Background:

• Tyrosine kinase inhibitors (TKIs) are a vital class of anti-cancer drugs.
• Sunitinib is a standard first-line therapy for metastatic renal cancer.
• Thyroid dysfunction is a known toxicity associated with TKIs.

Observation:

• This case report details a patient who developed severe hypothyroidism.
• The hypothyroidism was induced by sunitinib treatment.
• The patient experienced significant cardiac compromise as a result.

Findings:

• Sunitinib can cause severe hypothyroidism.
• Hypothyroidism in patients on sunitinib can lead to cardiac compromise.
• Thyroid function monitoring is essential during TKI therapy.

Implications:

• Highlights the need for vigilant thyroid function monitoring in patients undergoing TKI therapy.
• Emphasizes the potential for severe adverse events, including cardiac issues, from TKI-induced hypothyroidism.
• Informs clinical practice regarding the management of patients receiving sunitinib and similar TKIs.